Award recordCONTRACT

NOVARTIS PHARMACEUTICALS CORPORATION

PIID 36C25725N0376· VHA· 257-NETWORK CONTRACT OFFICE 17 (36C257)· 6505 · DRUGS AND BIOLOGICALS· FY2025· $857,357 net obligations· UEI NG61ZA8TADW3· NJ

Description

PLUVICTO - OY1

Base award description: PLUVICTO

First action · last action
2025-06-16 · 2026-04-27
Transactions
3
First transaction's obligation
$431,979
Base + all options value (sum of deltas)
$857,357
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
36F79720D0180
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 3 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$857,357$0Base award · 2025-06-16 · this action $431,979 · running total $431,979Modification P00001 · 2026-04-16 · this action -$20,448 · running total $411,531Modification P00002 · 2026-04-27 · this action $445,825 · running total $857,357
  • Base2025-06-16+$431,979= $431,979
  • Mod P000012026-04-16-$20,448= $411,531
  • Mod P000022026-04-27+$445,825= $857,357
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2025-06-16+$431,979$431,979PLUVICTO
Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE2026-04-16−$20,448$411,531PLUVICTO - QUANTITY DECREASE
Mod P00002· EXERCISE AN OPTION2026-04-27+$445,825$857,357PLUVICTO - OY1

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI NG61ZA8TADW3)

AwardOffice · PSC / listingNet obligationsFY
36C25526N0394255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS$891,651FY2026
36C26226F0314262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS$823,062FY2026
36C24526N0724245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$34,874FY2026
36C24526N0622245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$34,874FY2026
36C25026N0416250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS$617,297FY2026
36C24526N0566245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$34,874FY2026

Other recipients under 6505 from 257-NETWORK CONTRACT OFFICE 17 (36C257) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C25726N0367ISORX TEXAS LTD257-NETWORK CONTRACT OFFICE 17 (36C257)$53,945FY2026
36C25726N0407CARDINAL HEALTH 414, LLC257-NETWORK CONTRACT OFFICE 17 (36C257)$1,400,000FY2026
36C25726P0476PETNET SOLUTIONS, INC.257-NETWORK CONTRACT OFFICE 17 (36C257)$40,573FY2026
36C25726P0423PANHANDLE NUCLEAR RX, LTD.257-NETWORK CONTRACT OFFICE 17 (36C257)$325,038FY2026
36C25726N0316PROGENICS PHARMACEUTICALS INC257-NETWORK CONTRACT OFFICE 17 (36C257)$721,744FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25725N0376_3600_36F79720D0180_3600 · retrieved 2026-09-26.